Novartis rises to second place in 2018 Access to Medicine Index

NovartisNovartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to healthcare. Novartis remained the industry leader in access-to-medicine management, and its newly launched Access Principles - which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally - have been highlighted as an innovative practice. The Novartis CEO and members of the Executive Committee now also have access objectives as part of their individual objectives.

The Index measures the performance of the top-20 pharmaceutical companies to improve access to medicines and healthcare in developing countries. It covers seven categories: access-to-medicine management; market influence and compliance; R&D; pricing, manufacturing and distribution; patents and licensing; capacity building; and product donations.

"We are delighted that the Access to Medicine Index has recognized our actions to expand access to medicines and healthcare to underserved patients," said Vasant Narasimhan, CEO of Novartis. "It is a testimony to how our approach is evolving, from philanthropy to scalable and sustainable approaches, and to our commitment to systematically embed access into our business model. We have a long journey ahead of us, and we are committed to doing more to help get our therapies to more patients that need them."

Novartis rose to 3rd place in the R&D category in recognition of its systematic approach to assessing its portfolio against the unmet needs of underserved populations through a dedicated unit. The company rose 13 spots to 2nd place in market influence and compliance. The ATMi recognized our improved performance in internal controls and transparency, including financial support to patient groups. Novartis also performed strongly on product donations, in particular thanks to the wide geographic coverage of its leprosy program in 49 countries.

Among the recognized best practices are the dedicated R&D unit to adapt medicines to the needs of patients in low- and middle-income countries; Novartis Access, our portfolio of medicines against chronic diseases for USD 1 per treatment per month, which was expanded to new countries in Africa and Asia; SMS for Life, which uses mobile technology to manage medicine stocks, train healthcare workers and track disease surveillance data; and ComHIP, supported by the Novartis Foundation and its partners to improve hypertension control and self-management in Ghana. Further, the company's initiatives to strengthen care at community level and its approach to valuing the financial, environmental and social impact of its business activities on society are also highlighted.

Expanding access is complex, and despite our best efforts, there are still opportunities to do more to help ensure our innovation reaches more people. As opportunities for improvement for Novartis, the ATMi identified further embedding our access principles, expanding equitable pricing strategies to cover more countries and leveraging voluntary licensing opportunities.

In addition to the ATMi, Novartis participates in several key sustainability questionnaires and ratings such as the Dow Jones Sustainability Index, Sustainalytics, CDP, Vigeo and Oekom, and systematically engages with analysts on its sustainability performance. In 2018, Novartis was again included in the Dow Jones Sustainability World Index (#4) and the DJSI Europe Index. Novartis was also included in several reputation and innovation rankings, including the Thomson Reuters Diversity & Inclusion Index (#2), the Nature Index (#3), the Pharmaceutical Innovation Index (#3) and PatientView's reputation survey (#4). And we were recognized as one of the most sustainable corporations (#64) by Corporate Knights, one of the World's Most Innovative Companies (#1 in biotech and #21 overall) by Fast Company and one of the most admired pharmaceutical companies (#3) by Fortune.

Novartis pursues a combination of approaches to expand access to its medicines - philanthropy, zero-profit initiatives, equitable pricing strategies and social business models. In 2017, the company reached 46 million patients globally through its access-to-healthcare initiatives, and 15 million people through health education programs.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world.

Most Popular Now

AstraZeneca takes next steps towards broad and equ…

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements ...

Johnson & Johnson announces acceleration of it…

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Calquence showed promising clinical improvement in…

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved cl...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

New consortium EUbOPEN will provide tools to unloc…

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to bet...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...